| |
Dapagliflozin (n = 40)
|
Sitagliptin (n = 40)
|
p valueb
|
|---|
|
Pre treatment
|
Post treatment
|
% change
|
p valuea
|
Pre treatment
|
Post treatment
|
% change
|
p valuea
|
|---|
|
Total-C (mg/dL)
|
193.5 ± 36.6
|
198.4 ± 45.9
|
2.5
|
0.863
|
192.5 ± 58.2
|
195.5 ± 38.9
|
1.6
|
0.720
|
0.102
|
|
TG (mg/dL)
|
152.6 ± 63.7
|
133.7 ± 75.8
|
−12.4
|
0.145
|
150.2 ± 85.2
|
144.6 ± 87.2
|
−3.7
|
0.245
|
0.928
|
|
HDL-C (mg/dL)
|
48.4 ± 11.1
|
53.5 ± 13.0
|
10.5
|
<0.001*
|
50.3 ± 9.25
|
50.3 ± 11.1
|
0
|
0.948
|
0.003*
|
|
LDL-C (mg/dL)
|
118.2 ± 32.1
|
118.8 ± 39.7
|
0.5
|
0.875
|
120.2 ± 35.1
|
114.7 ± 33.1
|
−4.6
|
0.257
|
0.323
|
|
Non HDL-C (mg/dL)
|
145.1 ± 36.0
|
144.9 ± 439
|
−0.1
|
0.947
|
142.2 ± 57.3
|
145.1 ± 38.4
|
2.9
|
0.717
|
0.328
|
|
Apo AI (mg/dL)
|
133.5 ± 21.6
|
143.5 ± 22.6
|
7.5
|
0.002*
|
134.9 ± 25.2
|
128.8 ± 30.7
|
−4.5
|
0.135
|
0.002*
|
|
Apo AII (mg/dL)
|
29.7 ± 4.5
|
30.9 ± 5.0
|
4.0
|
0.022*
|
30.5 ± 7.2
|
30.5 ± 7.2
|
0
|
0.945
|
0.148
|
|
Apo B (mg/dL)
|
100.1 ± 24.5
|
100.8 ± 28.1
|
0.7
|
0.777
|
102.3 ± 27.7
|
97.4 ± 26.5
|
−4.8
|
0.123
|
0.131
|
|
Apo CII (mg/dL)
|
4.8 ± 1.7
|
4.9 ± 2.2
|
2.1
|
0.362
|
5.4 ± 2.8
|
5.1 ± 2.6
|
−5.6
|
0.197
|
0.105
|
|
Apo CIII (mg/dL)
|
10.5 ± 3.2
|
11.4 ± 4.3
|
8.6
|
0.021*
|
10.1 ± 4.5
|
9.6 ± 4.0
|
−5.0
|
0.335
|
0.028*
|
|
Apo E (mg/dL)
|
4.4 ± 1.2
|
4.4 ± 1.5
|
0
|
0.530
|
4.3 ± 1.5
|
4.1 ± 1.0
|
−4.7
|
0.296
|
0.216
|
|
RLP-C (mg/dL)
|
6.8 ± 4.3
|
6.4 ± 5.1
|
−5.9
|
0.620
|
6.9 ± 8.0
|
6.1 ± 5.7
|
−11.6
|
0.303
|
0.750
|
|
HDL2-C (mg/dL)
|
26.1 ± 8.2
|
30.8 ± 10.8
|
18.0
|
<0.001*
|
26.6 ± 7.9
|
27.5 ± 8.4
|
3.4
|
0.334
|
0.013*
|
|
HDL3-C (mg/dL)
|
22.2 ± 3.9
|
22.7 ± 5.0
|
2.3
|
0.527
|
23.3 ± 5.2
|
22.2 ± 5.3
|
−4.7
|
0.132
|
0.130
|
|
sd LDL-C (mg/dL)
|
54.4 ± 24.6
|
43.6 ± 24.4
|
−19.9
|
0.005*
|
54.0 ± 22.5
|
50.4 ± 22.4
|
−6.7
|
0.368
|
0.003*
|
|
lb LDL-C (mg/dL)
|
63.8 ± 27.6
|
75.1 ± 34.1
|
17.7
|
0.026*
|
66.2 ± 26.3
|
64.3 ± 24.1
|
−2.9
|
0.671
|
0.029*
|
- Data are expressed as mean ± standard deviation or percent changes after the treatment
-
Total-C total-cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, Apo apolipoprotein, RLP-C remant-like particles-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol
-
ap values for the intragroup comparison (pre vs. post treatment values in dapagliflozin or sitagliptin group, * p < 0.05)
-
bp values for intergroup comparison (dapagliflozin vs. sitagliptin group in the changes from pre to post treatment, * p < 0.05)
